2-pyridylacetic acid chloride | 144659-13-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-pyridylacetic acid chloride
• 英文别名: 2-Pyridineacetylchloride；2-(pyridin-2-yl)-acetyl chloride；pyridin-2-ylacetyl chloride；2-pyridylacetyl chloride；(2-pyridinyl) acetyl chloride；2-(Pyridin-2-yl)acetyl chloride；2-pyridin-2-ylacetyl chloride
• CAS: 144659-13-2
• 化学式: C₇H₆ClNO
• 分子量: 155.584
• InChiKey: JMZMVURYVHXGKK-UHFFFAOYSA-N

物化性质

• 熔点：
  118 °C
• 沸点：
  231.0±23.0 °C(Predicted)
• 密度：
  1.254±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-pyridylacetic acid chloride 在 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 cyclopentyl 2-(2-(pyridin-2-yl)acetamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate
  参考文献：
  名称：

  Thiophene inhibitors of PDE4: Crystal structures show a second binding mode at the catalytic domain of PDE4D2

  摘要：

  PDE4 inhibitors have been identified as therapeutic targets for a variety of conditions, particularly inflammatory diseases. We have serendipitously identified a novel class of phosphodiesterase 4 (PDE4) inhibitor during a study to discover antagonists of the parathyroid hormone receptor. X-ray crystallographic studies of PDE4D2 complexed to four potent inhibitors reveal the atomic details of how they inhibit the enzyme and a notable contrast to another recently reported thiophene-based inhibitor. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.109
• 作为产物：
  描述：

  2-吡啶乙酸盐酸盐 在 五氯化磷 作用下， 以 乙酰氯 为溶剂， 反应 4.5h， 生成 2-pyridylacetic acid chloride
  参考文献：
  名称：

  Thiophene inhibitors of PDE4: Crystal structures show a second binding mode at the catalytic domain of PDE4D2

  摘要：

  PDE4 inhibitors have been identified as therapeutic targets for a variety of conditions, particularly inflammatory diseases. We have serendipitously identified a novel class of phosphodiesterase 4 (PDE4) inhibitor during a study to discover antagonists of the parathyroid hormone receptor. X-ray crystallographic studies of PDE4D2 complexed to four potent inhibitors reveal the atomic details of how they inhibit the enzyme and a notable contrast to another recently reported thiophene-based inhibitor. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.109

文献信息

• Compounds useful for inhibiting Chk1
  申请人：——

  公开号：US20030069284A1

  公开（公告）日：2003-04-10

  Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.

  公开了芳基和杂芳基取代脲化合物，用于治疗与DNA损伤或DNA复制中DNA损伤有关的疾病和状况。还公开了制造这些化合物的方法，以及它们作为治疗剂的使用，例如，在治疗由DNA复制、染色体分离或细胞分裂缺陷引起的癌症和其他疾病。
• [EN] THIAZOLECARBOXAMIDE DERIVATIVES FOR USE AS NAMPT INHIBITORS<br/>[FR] DÉRIVÉS DE THIAZOLECARBOXAMIDE UTILES EN TANT QU'INHIBITEURS DE LA NAMPT
  申请人：ABBVIE INC

  公开号：WO2013170118A1

  公开（公告）日：2013-11-14

  Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.

  揭示了抑制NAMPT活性的化合物，包含这些化合物的组合物以及治疗NAMPT表达期间的疾病的方法。
• [EN] METHODS FOR PREPARATION OF BILE ACIDS AND DERIVATIVES THEREOF<br/>[FR] PROCÉDÉS DE PRÉPARATION D'ACIDES BILIAIRES ET DE LEURS DÉRIVÉS
  申请人：INTERCEPT PHARMACEUTICALS INC

  公开号：WO2017019524A1

  公开（公告）日：2017-02-02

  The present application relates to a method of preparing compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, R1 is H, α-OH, β-ΟΗ, or an oxo group.

  本申请涉及一种制备化合物I的方法或其药学上可接受的盐、溶剂化合物或氨基酸结合物的方法，其中R1为H、α-OH、β-OH或氧基团。
• Novel 3-aryl-2,5-dihydroxy-1,4-benzoquinone derivatives, their preparation method and pharmaceutical compositions containing same
  申请人：Dassonville Alexandra

  公开号：US20050085644A1

  公开（公告）日：2005-04-21

  Compound of formula (I): wherein: R 1 and R 2 , which may be identical or different, each represents hydrogen, acyl or alkyl, Ar represents aryl or heteroaryl, A represents a group selected from: R 4 represents hydrogen or alkyl, R 5 represents hydrogen, alkyl, aryl or heteroaryl, R 3 represents aryl, heteroaryl, dicyclopropylmethyl or benzhydryl, or A-R 3 represents an optionally substituted naphthyl group, with the exclusion of 2,5-dihydroxy-3-(4-methoxyphenyl)-6-(2-phenylethenyl)-1,4-benzoquinone, 2,5-dihydroxy-3-(4-methoxyphenyl)-6-(2-naphthyl)-1,4-benzoquinone and 2,5-dihydroxy-3-(2-naphthyl)-6-phenyl-1,4-benzoquinone. Medicinal products containing the same which are useful in the treatment of diseases associated with a deregulation of glycaemia.

  化合物的化学式（I）如下：其中：R1和R2，可能相同也可能不同，分别代表氢、酰基或烷基，Ar代表芳基或杂环芳基，A代表从以下选取的基团之一：R4代表氢或烷基，R5代表氢、烷基、芳基或杂环芳基，R3代表芳基、杂环芳基、二环丙基甲基或苄基，或A-R3代表一个可选择取代的萘基团，但不包括2,5-二羟基-3-(4-甲氧基苯基)-6-(2-苯乙烯基)-1,4-苯醌，2,5-二羟基-3-(4-甲氧基苯基)-6-(2-萘基)-1,4-苯醌和2,5-二羟基-3-(2-萘基)-6-苯基-1,4-苯醌。含有这种化合物的药品在治疗与血糖失调相关的疾病方面具有用途。
• Method for the treatment of cardiac failure with alkanoylimidazol-2-one
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US04367236A1

  公开（公告）日：1983-01-04

  4-Alkanoylimidazol-2-ones of the following general structure which are useful as cardiotonics in the treatment of cardiac failure ##STR1## wherein Q and T are each an oxygen atom or a divalent sulfur atom; R is hydrogen, lower alkyl, lower alkylcarbonyl or benzoyl; R.sub.1 is hydrogen or lower alkyl; R.sub.2 is a lower aliphatic hydrocarbon radical, phenyl alkylene or heterocyclo alkylene; and the pharmaceutically acceptable salts thereof.

  以下一般结构的4-癸酰基咪唑酮在治疗心力衰竭中作为心力药物是有用的，其中Q和T分别是氧原子或二价硫原子；R是氢、较低烷基、较低烷基羰基或苯甲酰基；R.sub.1是氢或较低烷基；R.sub.2是较低脂肪烃基、苯基烷基或杂环烷基；以及其药用可接受的盐。